SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN Limited is generating massive investor interest as the market anticipates an upcoming earnings report, with community members heavily debating whether the company will announce a transformative partnership deal. The stock's recent price surge has led to a contentious tug-of-war between retail bulls anticipating a breakout and short sellers betting on a post-earnings pullback.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing heightened volatility and community debate as investors weigh the company's recent earnings report against its long-term growth potential and aggressive short interest. While some shareholders are viewing price dips as a buying opportunity to capitalize on recent enterprise contract wins, others are expressing frustration over recurring sell-offs and the influence of short-sellers on the stock's immediate movement.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing intense community speculation as investors position themselves ahead of upcoming earnings, with many focusing on signs of improved unit economics and potential margin expansion under new leadership. The stock is trending as shareholders anticipate that favorable guidance could finally trigger a reversal of recent bearish sentiment and drive upward momentum.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave remains at the center of investor debate as the market weighs its massive $99.4 billion revenue backlog against concerns over mounting debt and widening quarterly losses. While some investors interpret the spending as necessary infrastructure buildout for an AI supercycle, others are heavily focused on the company's capital-intensive business model and a history of post-earnings volatility.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing extreme volatility as investors speculate on a potential short squeeze ahead of earnings, fueled by recent insider buying and ongoing rumors of a partnership with OpenAI. The community remains deeply polarized, with many retail investors expressing frustration over consistent post-earnings sell-offs while others position themselves for a significant breakout based on valuation and potential AI-driven growth.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently the center of investor attention as they prepare for a highly anticipated earnings report, with the community closely tracking the acquisition of Motiv Space Systems and progress on the Neutron launch vehicle. Shareholders are actively debating the company's long-term growth trajectory and vertical integration strategy, viewing these developments as key catalysts that could separate the stock from broader sector volatility.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is facing intense scrutiny as investors weigh upcoming earnings against a significant 14% workforce reduction aimed at optimizing operations for an AI-native strategy. The community remains deeply divided, with some betting on a rally driven by progress on the CLARITY Act and institutional adoption, while others are aggressively shorting the stock, citing poor historical performance and ongoing concerns over the company's cost structure.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing extreme volatility as investors weigh the company's aggressive capacity expansion against weak earnings and broader concerns about the sustainability of the AI infrastructure boom. The community remains deeply divided, with bulls pointing to robust demand for high-speed optical transceivers and recent government grants, while skeptics warn of a speculative bubble and poor fundamental performance.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors digest a mixed bag of earnings, with the community actively debating whether the company's strong revenue beat and maintained guidance justify its valuation or if ongoing legislative uncertainty and management's stock sales warrant skepticism. While some bulls are looking for a turnaround driven by the new Super App and prediction market growth, others remain frustrated by persistent selling pressure and the stock's lack of consistent upward momentum.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is capturing significant attention as investors react to a record-breaking earnings report that highlighted strong revenue growth, increased guidance, and expanding engagements with hyperscalers. Community sentiment is overwhelmingly bullish, with many traders actively discussing the potential for a massive short squeeze and long-term upside as the company solidifies its critical role in LLM data engineering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Allarity Therapeutics, Inc. (ALLR) on Tuesday announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its Stenoparib. Following the announcement, shares of the company more than doubled in value by Tuesday afternoon.Stenoparib is an investigational treatment for patients with advanced ovarian cancer. FDA’s Fast Track designation is intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need. It allows for more frequent interactions with the FDA throughout the drug development process and potentially provides eligibility for accelerated approval and priority review, upon meeting relevant criteria.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALLR">ALLR stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:575/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_26_at_12_16_43_PM_png_5d0f99e451.webp" alt="ALLR's Sentiment Meter and Message Volume as of 12:17 p.m. ET on Aug. 26, 2025 | Source: Stocktwits" width="575" height="61"><figcaption>ALLR's Sentiment Meter and Message Volume as of 12:17 p.m. ET on Aug. 26, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed surprise at the rally and opined that the stock might drop to below $1 by the end of the day.<stembedurl>https://stocktwits.com/patb99/message/626594104</stembedurl>Another user stated that larger pharmaceutical companies will now be interested in the drug.<stembedurl>https://stocktwits.com/Creyedr/message/626587898</stembedurl>Allarity CEO Thomas Jensen <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/26/3139198/0/en/Allarity-Therapeutics-Granted-FDA-Fast-Track-Designation-for-Stenoparib-for-the-Treatment-of-Advanced-Ovarian-Cancer.html">said</a> the company is pleased with the designation. “We look forward to engaging closely with the FDA as we advance this program,” he added.US-headquartered Allarity started patient enrollment under a new mid-stage clinical trial protocol evaluating Stenoparib in advanced, recurrent, platinum-resistant, or platinum-ineligible ovarian cancer in early June 2025. Several patients have already been dosed in the study. The trial is designed to accelerate clinical development of Stenoparib. Previous mid-stage study data showed durable clinical benefit for Stenoparib.The therapy was originally developed by Eisai Co., but Allarity secured exclusive global rights for the development and commercialization.ALLR stock has gained 74% this year but has lost 59% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-stock-rallies-after-therapy-for-autoimmune-disease-meets-late-stage-trial-goals/chsvb4wRdjv">Regeneron Stock Rallies After Therapy For Autoimmune Disease Meets Late-Stage Trial Goals: Retail Thinks Stock Might Hit An All-Time Low Soon</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Allarity Therapeutics Stock Double In Value Today?

The company’s Stenoparib, an investigational treatment for patients with advanced ovarian cancer, was granted the Fast Track designation by the FDA.

Equity

ReShape Lifesciences Inc. (1,900% Jump in Message Volume)ReShape Lifesciences saw a surge in retail discussion as traders speculated on the potential approval of its proposed reverse merger with Vyome Therapeutics, first announced in June 2024.&nbsp;The metabolic health solutions company stated in January that it was still working with the SEC on its S-4 filing and would set a shareholder meeting date once the filing is declared effective.Some investor interest also stemmed from reports that Michael Bigger’s fund had taken a significant stake in ReShape. However, sentiment remained mixed after the company raised $6 million through a public offering last month.&nbsp;ReShape’s stock is down nearly 80% year-to-date (YTD).Allarity Therapeutics Inc. (1,700% Jump in Message Volume)Allarity drew attention after announcing a Phase 2 trial evaluating the combination of stenoparib, a PARP inhibitor, with the chemotherapy agent temozolomide for treating recurrent small-cell lung cancer (SCLS). Prior studies had shown about a 40% response rate in SCLC patients, but dose-limiting toxicity remained a challenge.Additionally, Allarity’s Board of Directors authorized a $5 million share repurchase program on Monday, allowing buybacks through February 2026.&nbsp;The stock is down over 9% YTD.Exact Sciences Corporation (1,100% Jump in Message Volume)Exact Sciences, known for its cancer diagnostics, saw increased interest as it participated in the TD Cowen 45th Annual Healthcare Conference and Raymond James &amp; Associates’ 46th Annual Institutional Investors Conference last week.&nbsp;The company reiterated its plans to launch three new cancer screening tests in 2025, including Cologuard Plus (a next-generation colorectal cancer screening test), Oncodetect (a molecular residual disease test) and Cancerguard (a multi-cancer screening test).The company noted rising demand for rescreens, which grew 30% last year and are expected to grow another 30% this year.&nbsp;Exact Sciences’ stock is down over 18% YTD.CVS Health Corporation (700% Jump in Message Volume)CVS Health made headlines last week after announcing that Wellvana had acquired its Medicare Shared Savings Program business in an all-stock deal, giving CVS a strategic minority stake in Wellvana.On Saturday, The Wall Street Journal <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/business/retail/cvs-small-store-openings-b0e196a2">reported</a> that CVS plans to open a dozen new stores focused on full-service pharmacies with minimal retail space, a shift in response to declining retail sales across drugstore chains.&nbsp;The stock has gained 47% YTD.AbbVie Inc. (500% Jump in Message Volume)AbbVie’s stock gained traction after BofA raised its price target to $223 from $200, maintaining a ‘Neutral’ rating. The bullish revision followed AbbVie’s $350 million upfront deal with Gubra to develop GUB014295, a long-acting amylin analog targeting obesity.Under the agreement, Gubra could receive up to $1.88 billion in milestone payments, plus tiered royalties on global net sales.&nbsp;AbbVie shares are up nearly 20% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week

Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a  Medicare business deal, and an obesity drug partnership sparked buzz among Stocktwits users for the week ended March 7, 2025.

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.

ALLR
Allarity Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ALLR News

ALLRAllarity Therapeutics Inc